Aurinia Pharmaceuticals Inc.
AUPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600620
In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 282 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Aurinia Pharmaceuticals Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 191
- +27 vs. Q3 2021
- Shares held
- 39.2M
- −4.52M (−10.4%) vs. Q3 2021
- Total value
- $895.1M
- −$68.5M (−7.1%) vs. Q3 2021
- New holders
- 53
- 60 more added
- Sold out
- 26
- 55 more reduced
3 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 282 | $1.34B |
| Q1 2026 | 260 | $1.10B |
| Q4 2025 | 256 | $1.15B |
| Q3 2025 | 242 | $729.8M |
| Q2 2025 | 219 | $497.1M |
| Q1 2025 | 214 | $504.1M |
| Q4 2024 | 200 | $525.4M |
| Q3 2024 | 183 | $428.9M |
| Q2 2024 | 171 | $319.9M |
| Q1 2024 | 178 | $280.8M |
| Q4 2023 | 191 | $485.4M |
| Q3 2023 | 198 | $395.2M |
| Q2 2023 | 200 | $487.5M |
| Q1 2023 | 186 | $553.5M |
| Q4 2022 | 192 | $223.1M |
| Q3 2022 | 189 | $420.5M |
| Q2 2022 | 199 | $509.9M |
| Q1 2022 | 184 | $532.9M |
| Q4 2021 | 191 | $895.1M |
| Q3 2021 | 167 | $966.8M |
| Q2 2021 | 167 | $640.9M |
| Q1 2021 | 170 | $682.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Aurinia Pharmaceuticals Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Blackcrane Capital, LLC | 0 | $0 | 0.00% | −111,608−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −51,900−100.0% | Sold out |
| Advisory Research Inc | 0 | $0 | 0.00% | −49,141−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −22,904−100.0% | Sold out |
| MYDA Advisors LLC | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Bridgewater Associates, LP | 0 | $0 | 0.00% | −12,802−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −12,600−100.0% | Sold out |
| Gofen & Glossberg LLC | 0 | $0 | 0.00% | −9,500−100.0% | Sold out |
| Brown Brothers Harriman & Co | 0 | $0 | 0.00% | −6,500−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −3,225−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −2,945−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −700−100.0% | Sold out |
| Glen Eagle Advisors, LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Jacobi Capital Management LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Pacifica Partners Inc. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Omni Partners US LLC | – | – | – | – | Not filed |
| Knott David M | – | – | – | – | Not filed |
| Harbor Financial Services, LLC | – | – | – | – | Not filed |